Acute lung injury

ORIGINAL ARTICLE

Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat

Gerard F Curley,¹,² Mairead Hayes,¹,² Bilal Ansari,¹,² Georgina Shaw,³ Aideen Ryan,³ Frank Barry,³ Timothy O’Brien,³ Daniel O’Toole,²,³ John G Laffey¹,²,³

ABSTRACT

Background Bone-marrow derived mesenchymal stem cells (MSCs) reduce the severity of evolving acute lung injury (ALI), but their ability to repair the injured lung is not clear. A study was undertaken to determine the potential for MSCs to enhance repair after ventilator-induced lung injury (VILI) and elucidate the mechanisms underlying these effects.

Methods Anaesthetised rats underwent injurious ventilation which produced severe ALI. Following recovery, they were given an intravenous injection of MSCs (2×10⁶ cells) or vehicle immediately and a second dose 24 h later. The extent of recovery following VILI was assessed after 48 h. Subsequent experiments examined the potential for non-stem cells and for the MSC secretome to enhance VILI repair. The contribution of specific MSC-secreted mediators was then examined in a wound healing model.

Results MSC therapy enhanced repair following VILI. MSCs enhanced restoration of systemic oxygenation and lung compliance, reduced total lung water, decreased lung inflammation and histological lung injury and restored lung structure. They attenuated alveolar tumour necrosis factor α concentrations while increasing concentrations of interleukin 10. These effects were not seen with non-stem cells (ie, rat fibroblasts). MSC-secreted products also enhanced lung repair and attenuated the inflammatory response following VILI. The beneficial effect of the MSC secretome on repair of pulmonary epithelial wounds was attenuated by prior depletion of keratinocyte growth factor.

Conclusion MSC therapy enhances lung repair following VILI via a paracrine mechanism that may be keratinocyte growth factor-dependent.

INTRODUCTION

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are devastating diseases with a mortality of up to 40%, and for which there are no treatments.¹ Mortality from ALI/ARDS has fallen² as a result of advances in supportive care for sepsis, trauma and pneumonia and the demonstration that mechanical ventilation, while necessary for survival, has the capacity to cause significant harm.³ The importance of ventilator-induced lung injury (VILI) is underscored by the fact that ventilation strategies that reduce lung stretch save lives.³ The mechanisms whereby ventilation contributes to lung injury are increasingly well understood.⁴ However, more recent attempts to adjust ventilation strategies to further reduce harm have met with limited success.⁵ Even with contemporary low stretch strategies, it appears difficult to avoid regional areas of high lung stretch.⁶ In addition, low stretch strategies may worsen atelectasis,⁷ which can also cause harm.

An alternative approach is to develop strategies that enhance lung repair following VILI. Mesenchymal stem cells (MSCs) are fibroblast-like cells that can be isolated from bone marrow and are characterised by their ability to self-renew and undergo differentiation into mesenchymal lineage cell types including bone, cartilage, adipose tissue, muscle and tendon.⁸ MSCs have shown promise in a number of preclinical ALI/ARDS studies⁹ ¹⁰ and appear to exert immunomodulatory, anti-inflammatory and regenerative effects.⁵

The potential for MSCs to augment wound healing and repair after stretch-induced lung injury is not known. However, several factors suggest that they play a key role in the reparative response following injury,¹¹ and raise the possibility that transplanted MSCs may enhance restoration of organ function following injury. MSCs secrete growth factors and cytokines, which may play an important role in tissue regeneration and repair.¹² They can be found in increased numbers under
stress conditions, and both endogenous\textsuperscript{11} and transplanted\textsuperscript{13} MSCs appear to home to sites of injury. MSCs enhance tissue regeneration and wound repair in preclinical disease models and in clinical studies.\textsuperscript{14} In recent clinical studies, MSCs accelerated healing of cutaneous wounds and increased epithelialisation and angiogenesis.\textsuperscript{15}

Given these issues, we hypothesised that MSCs would enhance functional and structural recovery after VILI. We further hypothesised that this effect would be mediated, at least in part, via MSC-secreted soluble factors.

**MATERIALS AND METHODS**

All work was approved by the Animal Ethics Committee, National University of Ireland, Galway, and conducted under licence from the Department of Health, Ireland. A full description of the methods is given in the online supplement.

**MSC harvest and cell culture**

Rat MSCs (rMSCs) were isolated from adult male Sprague-Dawley rats. Following aspiration, the bone marrow was plated into tissue culture flasks. Adherent cells were grown until 80\% confluent and then trypsinised and culture expanded. Fibroblasts, used as control cells, were obtained from the dermis of adult Sprague-Dawley rats after digestion in 0.25\% trypsin.

Human MSCs (hMSCs) were aspirated from the iliac crests of healthy human volunteers and cultured until 80\% confluent, when they were harvested and expanded. Primary human lung fibroblasts and A549 lung adenocarcinoma cells were obtained from American Type Culture Collection (ATCC). MSCs were characterised according to international guidelines (see figures A and B in online supplement).\textsuperscript{16}

**Conditioned medium**

Rat and human MSCs and fibroblasts ($2 \times 10^6$) were washed and cultured without serum for 24 h. The cells were again washed and the subsequent serum-free medium for the next 24 h was used as the conditioned medium (CM). For in vivo experiments, 15 ml of this medium was concentrated using a 3000 Da centrifugal concentrating filter (Amicon, Billerica, Massachusetts, USA) to give 500 ml.

**Rodent ventilator-induced lung injury protocol**

The timeline for these experiments is depicted in figure 1. As previously described, adult male Sprague Dawley rats were anaesthetised, orotracheally intubated and subjected to injurious mechanical ventilation (inspiratory pressure 35 cm H$_2$O, respiratory rate 18/min and positive end expiratory pressure 0 cm H$_2$O).\textsuperscript{17} When respiratory static compliance had decreased by 50\%, the animals were recovered and entered into the treatment protocol.\textsuperscript{17}

**Assessment of injury and repair**

At 48 h following VILI induction, animals were re-anaesthetised and arterial blood gases and static inflation lung compliance

**Figure 1** Flow diagram indicating timelines for experimental interventions. MSCs, mesenchymal stem cells; PBS, phosphate-buffered saline; VILI, ventilator-induced lung injury.

**Figure 2** Mesenchymal stem cell (MSC) therapy enhances resolution following ventilation-induced lung injury. MSC therapy (A) decreased alveolar--arterial oxygen gradient ($p=0.04$), (B) increased static lung compliance ($p=0.003$), (C) reduced lung wet to dry weight ratios ($p=0.01$) and (D) decreased bronchoalveolar lavage (BAL) protein concentrations ($p=0.03$) 48 h after induction of severe stretch-induced lung injury compared with vehicle ($n=8$ animals per group). *$p<0.05$ vs vehicle.
measurements were performed. Post-mortem, bronchoalveolar lavage (BAL) differential cell counts, protein concentration and cytokine levels were determined. Wet to dry lung weight ratios were measured and histological lung damage was assessed.

**In vivo experimental series**
In the first series, after VILI the animals were randomly allocated to receive an intravenous injection of either $2 \times 10^6$ allogeneic rMSCs in 500 µl phosphate buffered saline (PBS) or 500 µl PBS alone. Twenty-four hours later a second injection of rMSCs or vehicle was administered (figure 1). In the second series, after VILI and at 24 h, animals received injections of $2 \times 10^6$ rMSCs, 500 µl PBS, $2 \times 10^6$ rat dermal fibroblasts or 500 µl rMSC-CM.

**Wound repair experiments**
An in vitro model of alveolar epithelial repair was used, as used in prior studies. Single wounds were made in confluent A549 monolayers in 24 well plates with a 1000 µl pipette tip. The wounds were exposed to different conditions according to group allocation. In the first experiment the wounds were incubated in MEM-α medium, human fibroblast CM, human MSC (hMSC)-CM or co-cultured with hMSCs. In the second experiment, hMSC-CM was incubated with monoclonal antibodies to inactivate keratinocyte growth factor (KGF), hepatocyte growth factor (HGF) and transforming growth factor β (TGF-β) (Abcam, Cambridge, UK), respectively. Wounds were exposed to hMSC-CM with and without antibodies to each candidate mediator. At 48 h the extent of epithelial restitution was determined (Photoshop v8.0, Adobe Systems, San Jose, California, USA).

**Statistical analysis**
Data were analysed using Sigma Stat (SYSTAT Software, Richmond, California, USA). The distribution of all data was tested for normality using Kolmogorov–Smirnov tests. Data were analysed by one-way ANOVA followed by the Dunnet test, with the vehicle group as the control group in each analysis. Comparisons between two groups were made using unpaired two-tailed Student t tests or a Mann–Whitney U test as appropriate. Underlying model assumptions were deemed appropriate on the basis of suitable residual plots. A two-tailed p value of <0.05 was considered significant.

**RESULTS**
In the first experimental series, 18 animals were entered into the study. Two animals died post-injury prior to randomisation, leaving eight animals per group. There were no differences between the groups at baseline with regard to animal weight and duration of injurious ventilation required to induce injury.

**MSCs restore lung function following VILI**
The administration of rMSCs enhanced recovery following VILI. rMSCs improved arterial oxygenation, as measured by the alveolar–arterial oxygen gradient (figure 2A), and enhanced restoration of static compliance compared with vehicle controls (figure 2B). rMSCs enhanced the restoration of lung microvascular permeability, as evidenced by a decrease in lung wet to dry weight ratios (figure 2C) and a decrease in alveolar fluid protein concentrations (figure 2D).

**MSCs modulate inflammation following VILI**
rMSCs reduced both total BAL cell count and BAL neutrophil counts (figure 3A). Alveolar concentrations of tumour necrosis factor α (TNF-α) (figure 3B) but not interleukin 6 (IL-6) (figure 3C) were decreased following rMSC treatment. In contrast,
alveolar concentrations of the anti-inflammatory cytokine IL-10 were increased in response to rMSC therapy (figure 3D).

**MSCs restore lung structure following VILI**

rMSCs decreased alveolar thickening, as evidenced by reduced alveolar tissue volume fraction, and increased recovery of airspace volume, as evidenced by increased alveolar airspace volume fraction (figures 4A,B). Representative histological sections of lung demonstrate the greater degree of resolution of injury and alveolar infiltrates in rMSC-treated animals (figure 4C,D).

**MSCs enhance repair via a paracrine mechanism**

In the second series, 40 animals (N=10 per group) underwent induction of severe VILI. There were no differences between the groups at baseline. Both rMSCs and rMSC-CM enhanced repair following VILI. In contrast, fibroblasts did not appear to exert beneficial effects. rMSCs and rMSC-CM enhanced the recovery of static lung compliance following VILI (figure 5A) and significantly reduced alveolar total cell and neutrophil infiltration (figure 5B), alveolar TNFα concentrations (figure 5C) and alveolar IL-6 concentrations (figure 5D). rMSCs and rMSC-CM significantly
increased serum, but not alveolar, IL-10 concentrations compared with animals treated with fibroblasts (data not shown).

**MSCs enhance pulmonary epithelial wound repair via a KGF-dependent mechanism**

Human MSC-CM increased the rate of wound closure in alveolar epithelial A549 monolayers subjected to scratch injury in comparison with fibroblast CM and fresh medium controls (figure 6A). The rate of wound closure seen with hMSC-CM was similar to that seen in hMSC co-cultures (figure 6A). In subsequent studies, prior incubation of hMSC-CM with antibodies to neutralise KGF attenuated its beneficial effects on wound repair (figure 6B). In contrast, incubation of hMSC-CM with antibodies to neutralise HGF and TGF-β did not alter wound repair (figure 6B). Measurement of KGF concentrations in the MSC and fibroblast CM showed that MSCs produced substantially greater amounts of KGF ($510\pm90$ vs $68\pm13$ pg/ml, $p<0.0001$).

**DISCUSSION**

MSCs have several properties that make them attractive as a potential treatment for ALI/ARDS. MSCs avoid allo-recognition, home to sites of injury and suppress inflammation as well as immune responses. Preclinical studies have shown that MSC therapy can attenuate endotoxin-induced ALI when given during the injury phase in both rodents and in the perfused human lung. Bone marrow-derived MSCs have also demonstrated benefit in preclinical sepsis models.

In these studies we have shown that MSCs enhance the recovery of lung function and structure following VILI. Specifically, rMSCs reduced the decrement in systemic oxygenation, restored static lung compliance, and enhanced alveolar fluid clearance following VILI, as evidenced by reduced BAL protein concentrations, reduced lung wet to dry weight ratios and histological evidence of reduced alveolar tissue oedema. These findings support previous findings that rMSCs enhance alveolar epithelial fluid transport in the endotoxin-injured ex vivo human lung via a KGF-dependent mechanism. The demonstration that rMSCs enhanced the recovery of lung function and structure following VILI is central to determining its therapeutic potential. Many promising therapies have demonstrated benefit in preclinical models when used prophylactically but have been less successful when used following injury.

MSCs decreased the inflammatory response following VILI. Specifically, rMSCs reduced alveolar inflammatory cell counts, particularly alveolar neutrophils. It is not clear whether rMSCs reduced neutrophil infiltration or enhanced neutrophil clearance. These findings support those of previous studies, which suggest that MSCs modulate the activity of T cells, B cells, dendritic cells, monocytes and macrophages. Recently reported that MSCs inhibited apoptosis and the oxidative burst of resting and activated neutrophils while preserving their phagocytic and chemotactic functions.

In our studies, MSCs modulated the cytokine response, decreasing alveolar TNFα and IL-6 concentrations. rMSC therapy increased alveolar IL-10 concentrations, a potentially important finding which has previously been reported. IL-10 is a cytokine secreted predominantly by monocytes that decreases the expression of Th1 cytokines, MHC class II antigens and co-stimulatory molecules on macrophages. IL-10 also inhibits the rolling, adhesion and transepithelial migration of neutrophils. Nemeth et al described a pivotal role for MSC-induced macrophage secretion of IL-10 in mediating the protective effects of MSCs in a murine caecal ligation and puncture sepsis model. Nemeth et al further showed that MSCs induced macrophage IL-10 secretion via secretion of prostaglandin E2.

MSCs enhanced repair following VILI via a paracrine mechanism, with rMSC-CM as effective as rMSCs themselves. To further dissect the mechanisms of action of MSCs, we focused on the potential for MSC secretion of KGF, TGF-β and HGF to contribute to repair. We found that depletion of KGF—but not TGF-β or HGF—from the MSC medium attenuated pulmonary epithelial wound healing. Given the importance of epithelial wound healing to restoration of lung structure following VILI and the previous demonstration that MSCs enhanced alveolar fluid clearance via a KGF-dependent mechanism, these findings suggest that KGF may be central to the reparative effects of MSCs in VILI.

The dose regimen used for these studies—namely, intravenous $2\times10^6$ rMSCs following recovery from VILI followed by a second dose 24 h later—was safe and effective with no adverse effects related to rMSC administration. However, other dosage regimens and other delivery routes such as the intratracheal or intraperitoneal routes may be equally effective in restoring lung function following VILI. Dermal fibroblasts were used as a potential treatment for ALI/ARDS.
a control non-stem cell because of their similarity to MSCs. Additional studies are needed to determine the optimal dosage regimen, including the minimally effective MSC doses and the best administration route.

There are a number of limitations to these studies. First, while we provide data to suggest that KGF secreted by MSCs contributes to repair following VILI, our data do not preclude a contribution by other mediators to the mechanisms by which MSCs enhance lung repair. Second, our in vivo studies were carried out in a rodent model and caution must be exercised in extrapolating to the clinical situation. However, in our intravenous studies were carried out in human cell lines and used human MSCs. When taken together with other studies examining the effects of MSCs during the injury phase of ALI/ARDS, these findings strongly suggest that MSCs may have therapeutic potential for ALI/ARDS. Third, we did not provide baseline data on these animals to allow the reader to assess the magnitude of effects of injurious ventilation on the parameters measured. However, the effect of the high stretch ventilation strategy used in this model has been well characterised in a previous publication from our group. Furthermore, we do not provide data for the effects of MSCs on protectively ventilated or unventilated lungs. However, it would be expected that any effects on these animals would be limited. Lastly, we did not study the effects of KGF supplemented or depleted MSC-CM in our in vivo studies. Inclusion of these groups might have provided important additional insights.

In conclusion, we have shown that bone marrow-derived MSCs enhance recovery after VILI when administered into the systemic circulation in the rat. The mechanism for this effect may be due to the secretion of paracrine soluble factors such as KGF by the MSCs themselves. MSC therapy may represent an innovative approach for treatment of VILI and ARDS.

**Funding** The European Research Council (grant number ERC-2007-StG 207777) and Health Research Board, Dublin, Ireland (grant number RP/2008/153) provided unrestricted funds for these studies. Dr Curley was supported by a fellowship from Molecular Medicine Ireland (HEA PRTLI Cycle A).

**Competing interests** None.

**Patient consent** Not needed.

**Contributors** JGL, GFC, TO’B, DOT and FB designed the study. GFC and MH performed the experiments. BA carried out the cytokine assays. GFC, AR and GS harvested and characterised the mesenchymal stem cells. JGL analysed the data. GFC, DOT and JGL drafted the manuscript and are guarantors of the paper.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**

Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat
Gerard F Curley, Mairead Hayes, Bilal Ansari, Georgina Shaw, Aideen Ryan, Frank Barry, Timothy O’Brien, Daniel O’Toole and John G Laffey

Thorax 2012 67: 496-501 originally published online November 21, 2011
doi: 10.1136/thoraxjnl-2011-201059

Updated information and services can be found at:
http://thorax.bmj.com/content/67/6/496

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2011/11/19/thoraxjnl-2011-201059.DC1

References
This article cites 28 articles, 11 of which you can access for free at:
http://thorax.bmj.com/content/67/6/496#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Adult respiratory distress syndrome (111)
- Inflammation (1020)
- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- TB and other respiratory infections (1273)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/